Novartis AG (NOVN) Given a CHF 80 Price Target at Goldman Sachs Group Inc
Novartis AG (VTX:NOVN) has been assigned a CHF 80 price target by equities research analysts at Goldman Sachs Group Inc in a note issued to investors on Saturday. The firm presently has a “neutral” rating on the stock.
Separately, JPMorgan Chase & Co. set a CHF 70 target price on shares of Novartis AG and gave the stock a “neutral” rating in a research note on Saturday.
Shares of Novartis AG (VTX:NOVN) traded up 0.13% during mid-day trading on Friday, hitting CHK 78.75. The company had a trading volume of 5,144,966 shares. Novartis AG has a one year low of CHK 67.40 and a one year high of CHK 82.80. The firm’s 50-day moving average price is CHK 76.13 and its 200 day moving average price is CHK 73.94.
WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/05/20/novartis-ag-novn-given-a-chf-80-price-target-at-goldman-sachs-group-inc.html.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.